Caraway Therapeutics

Caraway’s Targeted Approach Leverages Genetic Data and Unique Biological Insights to Develop Small Molecules that Activate Neuronal Clearance and Recycling Processes – Accelerating the Removal of Toxic Substances and Defective Cellular Components. New Genetic Insights Highlight the Connection Between the Lysosomal Processes That Normally Maintain Internal Neuronal Order and the Risk of Neurodegenerative Disease Progression. Caraway Is a Leader in Targeting These Mechanisms, Which Hold Potential for Disease-Modifying Compounds, Addressing Diseases Such as Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), and Lysosomal Storage Disorders.